Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
At Natural Resources Partners L.P. (NYSE:NRP), a filing with the SEC revealed that on Wednesday, Christopher Cline bought 756,914 shares of NRP, for a cost of $19.82 each, for a total investment of $15M. Cline was up about 13.0% on the buy at the high point of today's trading session, with NRP trading as high as $22.39 in trading on Friday. Natural Resources Partners L.P. is trading up about 1.8% on the day Friday. This purchase marks the first one filed by Cline in the past year.
And at Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), there was insider buying on Tuesday, by Director Philip A. Sharp who bought 4,967 shares at a cost of $20.13 each, for a total investment of $99,986. Before this latest buy, Sharp made one other purchase in the past twelve months, buying $99,996 shares for a cost of $10.75 each. Alnylam Pharmaceuticals Inc is trading up about 2% on the day Friday. So far Sharp is in the green, up about 21.4% on their purchase based on today's trading high of $24.44.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.